abstract |
The present invention discloses the identification of the new human tumor necrosis factor receptor homologue ('TRH1'), as identified by its nucleic acid and amino acid sequences disclosed herein. The invention also includes methods of using the nucleic acid sequence, the TRH1 protein, a monoclonal antibody specific for the novel tumor necrosis factor receptor, a ligand for the novel tumor necrosis factor receptor, and fusion proteins comprising all or a portion of the TRH1 disclosed herein. |